Conditions: Pneumonia
Keywords: Moxifloxacin
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 207
Healthy volunteers: no

Brief summary:
The purpose of this study is to Evaluate the Efficacy, safety and pharmacokinetics of Intravenous Nemonoxacin Compared with Intravenous Moxifloxacin in Adult Patients with community-acquired pneumonia (CAP).

Detailed description:
Community-acquired Pneumonia (CAP) remains a leading cause of death in both developing and developed countries. In the choice of antibacterial agents used to treat CAP, fluoroquinolones have received considerable attention because of their wide spectrum of bactericidal activity. TG-873870 (Nemonoxacin), a non-fluorinated quinolone (NFQ), is a selective bacterial topoisomerase inhibitor.

This study will Evaluate the clinical efficacy, microbiological efficacy and safety of Intravenous Nemonoxacin compared with Intravenous Moxifloxacin in adult patients with community-acquired pneumonia.

Besides, the pharmacokinetics (PK) of Nemonoxacin in adult patients with CAP after continuous IV Infusion and the pharmacokinetic (PK)/pharmacodynamic (PD)are to be determined.

Arms:
arm 1: Nemonoxacin 500mg/250mL. arm 2: Nemonoxacin 650 mg/325mL arm 3: Moxifloxacin 400mg/250mL

Interventions: intervention 1: Nemonoxacin 500 mg intervention 2: Nemonoxacin 650 mg intervention 3: Moxifloxacin 400 mg
Intervention descriptions: intervention 1: IV Infusion, once daily for 7\~14 days intervention 2: IV Infusion, once daily for 7\~14 days intervention 3: IV Infusion, once daily for 7\~14 days

Protocol document: